Annual fasting plasma glucose variation increases risk of cancer incidence and mortality in patients with type 2 diabetes: the Taichung Diabetes Study.

Abstract:

:The study aims to examine whether the annual variations in fasting plasma glucose (FPG) measurements, represented by the coefficient of variation (CV), predict cancer incidence and mortality in the subsequent years independent of traditional risk factors of type 2 diabetic patients. A computerized database of patients with type 2 diabetes of 30 years old and older (n=4805) enrolled in the Diabetes Care Management Program of a medical center before 2006 was analyzed using a time-dependent Cox's proportional hazards regression model. The mortality rates for the first, second, and third tertiles of the first annual FPG-CV were 8.64, 12.71, and 30.82 per 1000 person-years respectively. After adjusting for mean FPG, HbA1c, and other risk factors, the annual FPG-CV was independently associated with cancer incidence, cancer mortality, and cancer incidence or mortality, and the corresponding hazard ratios for the third vs first tertile of the annual FPG-CV were 3.03 (1.98, 4.65), 5.04 (2.32, 10.94), and 2.86 (1.91, 4.29) respectively. The annual variation in FPG was a strong predictor of cancer incidence and mortality in type 2 diabetic patients; therefore, glucose variation may be important in the clinical practice of care management and cancer prevention.

journal_name

Endocr Relat Cancer

journal_title

Endocrine-related cancer

authors

Lin CC,Li CI,Liu CS,Lin WY,Chen CC,Yang SY,Lee CC,Li TC

doi

10.1530/ERC-12-0038

subject

Has Abstract

pub_date

2012-07-18 00:00:00

pages

473-83

issue

4

eissn

1351-0088

issn

1479-6821

pii

ERC-12-0038

journal_volume

19

pub_type

杂志文章
  • Management of carcinoid syndrome: a systematic review and meta-analysis.

    abstract::Carcinoid syndrome (CS) is a debilitating disease caused by functional neuroendocrine tumors. Several treatment options are available to alleviate the hormonal symptoms, but their relative efficacy is unknown. Online databases were searched for publications on the treatment of CS symptoms. Independent reviewers assess...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,meta分析

    doi:10.1530/ERC-18-0495

    authors: Hofland J,Herrera-Martínez AD,Zandee WT,de Herder WW

    更新日期:2019-03-01 00:00:00

  • Tetrac as an anti-angiogenic agent in cancer.

    abstract::The thyroid hormones T3 and T4 have emerged as pro-angiogenic hormones with important implications for cancer management. Endogenous circulating hormone levels may help stimulate cancer progression and limit the effectiveness of anticancer therapy, though clinical data remain inconclusive. The capacity of thyroid horm...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-19-0058

    authors: Schmohl KA,Nelson PJ,Spitzweg C

    更新日期:2019-06-01 00:00:00

  • Obesity and menopause modify the epigenomic profile of breast cancer.

    abstract::Obesity is a high risk factor for breast cancer. This relationship could be marked by a specific methylome. The current work was aimed to explore the impact of obesity and menopausal status on variation in breast cancer methylomes. Data from Infinium 450K array-based methylomes of 64 breast tumors were coupled with in...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-16-0565

    authors: Crujeiras AB,Diaz-Lagares A,Stefansson OA,Macias-Gonzalez M,Sandoval J,Cueva J,Lopez-Lopez R,Moran S,Jonasson JG,Tryggvadottir L,Olafsdottir E,Tinahones FJ,Carreira MC,Casanueva FF,Esteller M

    更新日期:2017-07-01 00:00:00

  • Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.

    abstract::Elevated circulating chromogranin A (CgA) levels are found in neuroendocrine tumors (NETs), but the diagnostic usefulness of this marker is still debatable. To assess the role of CgA for the diagnosis of gastroenteropancreatic (GEP) NETs and the identification of metastatic patients, an Italian multicenter observation...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1677/ERC-07-0001

    authors: Zatelli MC,Torta M,Leon A,Ambrosio MR,Gion M,Tomassetti P,De Braud F,Delle Fave G,Dogliotti L,degli Uberti EC,Italian CromaNet Working Group.

    更新日期:2007-06-01 00:00:00

  • Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.

    abstract::Vandetanib is an oral tyrosine kinase inhibitor approved for treatment of advanced symptomatic or progressive medullary thyroid cancer (MTC). The current study (Nbib1496313) evaluated the benefit-risk of two starting doses of vandetanib in patients with symptomatic or progressive MTC. Patients were randomized 1:1 to r...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,随机对照试验

    doi:10.1530/ERC-18-0258

    authors: Hu MI,Elisei R,Dedecjus M,Popovtzer A,Druce M,Kapiteijn E,Pacini F,Locati L,Krajewska J,Weiss R,Gagel RF

    更新日期:2019-02-01 00:00:00

  • TRAP1 regulates cell cycle and apoptosis in thyroid carcinoma cells.

    abstract::Tumor necrosis factor receptor-associated protein 1 (TRAP1) is a heat shock protein 90 (HSP90) molecular chaperone upregulated in several human malignancies and involved in protection from apoptosis and drug resistance, cell cycle progression, cell metabolism and quality control of specific client proteins. TRAP1 role...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-16-0063

    authors: Palladino G,Notarangelo T,Pannone G,Piscazzi A,Lamacchia O,Sisinni L,Spagnoletti G,Toti P,Santoro A,Storto G,Bufo P,Cignarelli M,Esposito F,Landriscina M

    更新日期:2016-09-01 00:00:00

  • Body fatness as a cause of cancer: epidemiologic clues to biologic mechanisms.

    abstract::Carrying excess body fat is a leading cause of cancer. Epidemiologic evidence gives strong clues about the mechanisms that link excess adiposity to risk for several cancer sites. For postmenopausal breast cancer and endometrial cancer, the hyper-estrogenic state that is induced by excess body fatness is the likely cau...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-14-0580

    authors: Byers T,Sedjo RL

    更新日期:2015-06-01 00:00:00

  • Metabolic profiling of cholesterol and sex steroid hormones to monitor urological diseases.

    abstract::Cholesterol and sex steroid hormones including androgens and estrogens play a critical role in the development and progression of urological diseases such as prostate cancer. This disease remains the most commonly diagnosed malignant tumor in men and is the leading cause of death from different cancers. Attempts to un...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-16-0285

    authors: Moon JY,Choi MH,Kim J

    更新日期:2016-10-01 00:00:00

  • FSH inhibits ovarian cancer cell apoptosis by up-regulating survivin and down-regulating PDCD6 and DR5.

    abstract::Ovarian epithelial cancer is the leading cause of death among gynecological malignancies. FSH may increase the risk of ovarian malignancy and play an important role in ovarian carcinogenesis. Our previous studies showed that FSH increases the expression of VEGF through survivin. In this study, the function and mechani...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0308

    authors: Huang Y,Jin H,Liu Y,Zhou J,Ding J,Cheng KW,Yu Y,Feng Y

    更新日期:2010-11-30 00:00:00

  • Androgens, diabetes and prostate cancer.

    abstract::Metabolic disorders such as diabetes, obesity and the metabolic syndrome have been shown to modulate prostate cancer (PCa) risk and aggressiveness in population-based and experimental studies. While associations between these conditions are modest and complex, two consistent findings have emerged. First, there is obse...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-12-0067

    authors: Grossmann M,Wittert G

    更新日期:2012-09-05 00:00:00

  • Clinical aspects of cell death in breast cancer: the polyamine pathway as a new target for treatment.

    abstract::Because intracellular polyamines have a critical role in cell proliferation and death pathways, the polyamine metabolic pathway represents a potential target for intervention in cancers. A number of polyamine analogues have been identified that downregulate polyamine synthesis and enhance polyamine catabolism, thereby...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0060069

    authors: Davidson NE,Hahm HA,McCloskey DE,Woster PM,Casero RA Jr

    更新日期:1999-03-01 00:00:00

  • Overcoming oncogene addiction in breast and prostate cancers: a comparative mechanistic overview.

    abstract::Prostate cancer (PCa) and breast cancer (BCa) are both hormone-dependent cancers that require the androgen receptor (AR) and estrogen receptor (ER, ESR1) for growth and proliferation, respectively. Endocrine therapies that target these nuclear receptors (NRs) provide significant clinical benefit for metastatic patient...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-20-0272

    authors: Blatt EB,Kopplin N,Kumar S,Mu P,Conzen SD,Raj GV

    更新日期:2020-12-01 00:00:00

  • Factors regulating the growth of metastatic cancer in bone.

    abstract::Metastatic tumor cells can interfere directly with the function of bone cells involved in normal bone remodeling or indirectly by influencing the behavior of hematopoietic, stromal and other cells in bone marrow that interact with bone cells. Recent studies of metastatic cancer have revealed that tumor cells interact ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0060333

    authors: Boyce BF,Yoneda T,Guise TA

    更新日期:1999-09-01 00:00:00

  • The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours.

    abstract::Neuroendocrine neoplasms (NENs) are a relatively rare group of heterogeneous tumours originating from neuroendocrine cells found throughout the body. Pancreatic NENs (PanNENs) are the second most common pancreatic malignancy accounting for 1-3% of all neoplasms developing in the pancreas. Despite having a low backgrou...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-19-0175

    authors: Pipinikas CP,Berner AM,Sposito T,Thirlwell C

    更新日期:2019-08-01 00:00:00

  • M918V RET mutation causes familial medullary thyroid carcinoma: study of 8 affected kindreds.

    abstract::Germline mutations in codon 918 of exon 16 of the RET gene (M918T) are classically associated with multiple endocrine neoplasia type 2B (MEN 2B) with highly aggressive medullary thyroid cancer (MTC), pheochromocytoma and a unique phenotype. The objectives of this study are to describe the rare M918V RET mutation disco...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-16-0141

    authors: Martins-Costa MC,Cunha LL,Lindsey SC,Camacho CP,Dotto RP,Furuzawa GK,Sousa MS,Kasamatsu TS,Kunii IS,Martins MM,Machado AL,Martins JR,Dias-da-Silva MR,Maciel RM

    更新日期:2016-12-01 00:00:00

  • Inhibition of gap junction transfer sensitizes thyroid cancer cells to anoikis.

    abstract::Resistance to anoikis (matrix deprivation-induced apoptosis) is a critical component of the metastatic cascade. Molecular mechanisms underlying resistance to anoikis have not been reported in thyroid cancer cells. For an in vitro model of anoikis, we cultured follicular, papillary, and anaplastic thyroid cancer cell l...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-10-0289

    authors: Jensen K,Patel A,Klubo-Gwiezdzinska J,Bauer A,Vasko V

    更新日期:2011-09-20 00:00:00

  • Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors.

    abstract::Pancreatic neuroendocrine tumors (PanNETs) are rare in von Hippel-Lindau disease (VHL) but cause serious morbidity and mortality. Management guidelines for VHL-PanNETs continue to be based on limited evidence, and survival data to guide surgical management are lacking. We established the European-American-Asian-VHL-Pa...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-18-0100

    authors: Krauss T,Ferrara AM,Links TP,Wellner U,Bancos I,Kvachenyuk A,Villar Gómez de Las Heras K,Yukina MY,Petrov R,Bullivant G,von Duecker L,Jadhav S,Ploeckinger U,Welin S,Schalin-Jäntti C,Gimm O,Pfeifer M,Ngeow J,Hasse-Laza

    更新日期:2018-09-01 00:00:00

  • Endothelins and hypoxia-inducible factor in cancer.

    abstract::The endothelin system is a family of three similar small peptides, two G-protein-coupled receptors and two proteinases. Endothelins have several physiological roles, notably in embryonic differentiation and vascular homeostasis. Numerous types of tumour express endothelins and their regulation is often aberrant when c...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/ERC-07-0057

    authors: Grimshaw MJ

    更新日期:2007-06-01 00:00:00

  • MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine.

    abstract::The high degree of conservation in microRNA from Caenorhabditiselegans to humans has enabled relatively rapid implementation of findings in model systems to the clinic. The convergence of the capacity for genomic screening being implemented in the prevailing precision medicine initiative and the capabilities of microR...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-16-0525

    authors: Smith B,Agarwal P,Bhowmick NA

    更新日期:2017-05-01 00:00:00

  • Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review.

    abstract::Ghrelin is a hormone with multiple physiologic functions, including promotion of growth hormone release, stimulation of appetite and regulation of energy homeostasis. Treatment with ghrelin/ghrelin-receptor agonists is a prospective therapy for disease-related cachexia and malnutrition. In vitro studies have shown hig...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-16-0130

    authors: Sever S,White DL,Garcia JM

    更新日期:2016-09-01 00:00:00

  • lncRNA H19 binds VGF and promotes pNEN progression via PI3K/AKT/CREB signaling.

    abstract::Pancreatic neuroendocrine neoplasms (pNENs) are endocrine tumors arising in pancreas and is the most common neuroendocrine tumors. Mounting evidence indicates lncRNA H19 could be a determinant of tumor progression. However, the expression and mechanism of H19 and the relevant genes mediated by H19 in pNENs remain unde...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-18-0552

    authors: Ji M,Yao Y,Liu A,Shi L,Chen D,Tang L,Yang G,Liang X,Peng J,Shao C

    更新日期:2019-07-01 00:00:00

  • 15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma.

    abstract::Although anatomic imaging to assess the precise localization of pheochromocytomas/paragangliomas (PHEOs/PGLs) is unavoidable before any surgical intervention on these tumors, functional imaging is becoming an inseparable portion of the imaging algorithm for these tumors. This review article presents applications of th...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-15-0175

    authors: Castinetti F,Kroiss A,Kumar R,Pacak K,Taieb D

    更新日期:2015-08-01 00:00:00

  • Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.

    abstract::Metastatic duodenopancreatic neuro-endocrine tumors (dpNETs) are the most important disease-related cause of death in patients with multiple endocrine neoplasia type 1 (MEN1). Nonfunctioning pNETs (NF-pNETs) are highly prevalent in MEN1 and clinically heterogeneous. Therefore, management is controversial. Data on prog...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-19-0372

    authors: Sadowski SM,Pieterman CRC,Perrier ND,Triponez F,Valk GD

    更新日期:2020-06-01 00:00:00

  • mTOR inhibition, a potential novel approach for bronchial carcinoids.

    abstract::Although targeted therapy, including inhibitors of mammalian target of rapamycin (mTOR) and vascular endothelial growth factor, being developed for carcinoids arised from the gastrointestinal tract, treatment for locally advanced or metastatic bronchial carcinoids (BCs) remains lacking. Traditional cytotoxic chemother...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-10-0290

    authors: Dong M,Yao JC

    更新日期:2011-04-28 00:00:00

  • Human melanoma cells express functional receptors for thyroid-stimulating hormone.

    abstract::We have reported a high prevalence of hypothyroidism in the cutaneous melanoma population, suggesting that the pathologic hormonal environment of hypothyroidism promotes melanoma growth. The objective of this study was to test the hypothesis that TSH, which circulates at elevated levels in hypothyroid individuals, sti...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.1.01239

    authors: Ellerhorst JA,Sendi-Naderi A,Johnson MK,Cooke CP,Dang SM,Diwan AH

    更新日期:2006-12-01 00:00:00

  • Autophagy in endocrine tumors.

    abstract::Autophagy is an important intracellular process involving the degradation of cytoplasmic components. It is involved in both physiological and pathological conditions, including cancer. The role of autophagy in cancer is described as a 'double-edged sword,' a term that reflects its known participation in tumor suppress...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-15-0042

    authors: Weckman A,Rotondo F,Di Ieva A,Syro LV,Butz H,Cusimano MD,Kovacs K

    更新日期:2015-08-01 00:00:00

  • Hormone receptor status does not alter the effect of trastuzumab in breast cancer.

    abstract::Overexpression of human epidermal growth factor receptor 2 (HER2) predicts response to anti-HER2 therapy in breast cancer. We investigated whether hormone receptor (HR) status influences the treatment benefit of trastuzumab in patients with breast cancer. Data from 8338 patients with primary nonmetastatic breast cance...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-16-0084

    authors: Ignatov T,Eggemann H,Burger E,Costa SD,Ignatov A

    更新日期:2016-05-01 00:00:00

  • Identification of occult tumors by whole-specimen mapping in solitary papillary thyroid carcinoma.

    abstract::We undertook this study to estimate an accurate incidence and spread patterns of occult papillary thyroid carcinoma (PTC) in patients with a preoperative diagnosis of solitary PTC by using whole-specimen mapping of all specimens after a total thyroidectomy. Enrolled prospectively in this whole-thyroid mapping study ar...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-15-0152

    authors: Park SY,Jung YS,Ryu CH,Lee CY,Lee YJ,Lee EK,Kim SK,Kim TS,Kim TH,Jang J,Park D,Dong SM,Kang JG,Lee JS,Ryu J

    更新日期:2015-08-01 00:00:00

  • Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.

    abstract::In the CLARINET study, lanreotide Autogel (depot in USA) significantly prolonged progression-free survival (PFS) in patients with metastatic pancreatic/intestinal neuroendocrine tumours (NETs). We report long-term safety and additional efficacy data from the open-label extension (OLE). Patients with metastatic grade 1...

    journal_title:Endocrine-related cancer

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1530/ERC-15-0490

    authors: Caplin ME,Pavel M,Ćwikła JB,Phan AT,Raderer M,Sedláčková E,Cadiot G,Wolin EM,Capdevila J,Wall L,Rindi G,Langley A,Martinez S,Gomez-Panzani E,Ruszniewski P,CLARINET Investigators.

    更新日期:2016-03-01 00:00:00

  • Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome.

    abstract::Previous SNP array analyses have revealed genomic alterations of the Notch pathway as being the most frequent abnormality in adrenocortical tumors (ACTs). The aim of the present study was to evaluate the expression of components of Notch signaling in ACTs and to correlate them with clinical outcome. The mRNA expressio...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-15-0163

    authors: Ronchi CL,Sbiera S,Altieri B,Steinhauer S,Wild V,Bekteshi M,Kroiss M,Fassnacht M,Allolio B

    更新日期:2015-08-01 00:00:00